Antibody Therapy
Total Trials
1
As Lead Sponsor
As Collaborator
0
Total Enrollment
18
NCT04704323
CAP-100 for Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia
Phase: Phase 1
Role: Lead Sponsor
Start: Sep 10, 2021
Completion: Apr 30, 2027
Loading map...